What changes with Semaglutide?

What would a useful change look like?

A smaller appetite is one thing. A health benefit that matters to you is another. Semaglutide's label describes how it reduces food intake, but a treatment decision also needs a clear reason for using it.

In a weight-management trial, adults with obesity, or overweight plus a related condition, lost more weight on semaglutide than on a dummy injection. They didn't have diabetes, and both groups had lifestyle support. That finding is useful evidence, with room for individual results to differ.

A scale doesn't tell the whole story either. A 2026 review of trials across four related medicines found losses in lean tissue as well as fat. None of its included trials measured physical function objectively, so the review can't settle what those changes meant for strength. It doesn't supply a semaglutide-only estimate.

The stomach gets a vote

Nausea, vomiting, diarrhea and constipation are common. In adult weight-management trials listed in the Wegovy (semaglutide) injection label, 44 in 100 people on the medicine reported nausea, compared with 16 in 100 on a dummy injection. Those figures describe those trials, rather than every form of semaglutide.

A pooled trial analysis found digestive symptoms were usually mild to moderate and often started while researchers were increasing the dose. “Usually” leaves room for symptoms that are severe. Some people stopped treatment because of them.

Warnings worth knowing by name

The label warns about pancreatitis, meaning inflammation of the pancreas, and gallbladder disease. Severe belly pain that doesn't go away, sometimes spreading to the back, is a warning sign it describes. Serious vomiting or diarrhea can also cause dehydration and kidney injury.

The boxed warning concerns thyroid C-cell tumors found in rats and mice. Whether semaglutide causes them in humans is unknown. The label rules out use with a personal or family history of medullary thyroid carcinoma, a particular thyroid cancer, or MEN 2, an inherited condition.

Insulin and medicines such as sulfonylureas, which help the body release insulin, can raise the risk of low blood sugar when used with semaglutide. Existing eye damage from diabetes also matters. These are reasons for a full health-history discussion, rather than a quick yes or no based on appetite alone.

Think beyond the first change

In a follow-up to the weight-management trial, the group previously assigned semaglutide regained, on average, about two-thirds of its earlier weight loss during the year after treatment and the trial's lifestyle support stopped. It was a follow-up subset, not everyone's future written down. It makes what happens later a useful question now.

Questions can be simple: what benefit are we looking for, which symptoms need medical attention, and when will we review the plan? The prescription guide helps prepare for that discussion. There's room to be interested in a medicine and have reservations about it.